Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact - Endpoints News

Right on the heels of back-to-back breakthrough therapy designations for its lead RSV vaccine, Pfizer is wagering up to $525 million on a biotech buyout that injects new RSV assets into its pipeline. Pfizer is snapping up ReViral after inspecting mid-stage da…

As Congress grapples with how to reform and lower prescription drug costs and may have to settle for a $35 monthly insulin cap, new research points to the concerning extent to which seniors skip out … [+669 chars]

full article...